Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel J Sargent

Showing results (1-10 of 295) with videos related to

Pageof 30
Sort By:
Clinical Advances in Hematology & Oncology : H&O|September 17, 2005
Novel endpoints in phase III clinical trialsDaniel J Sargent
Clinical Advances in Hematology & Oncology : H&O|October 2, 2008
Advances in defective mismatch repair colon cancerDaniel J Sargent
Nature Reviews. Clinical Oncology|December 1, 2010
Chemotherapy: Failure of bevacizumab in early-stage colon cancerDaniel J Sargent
International Journal of Clinical Oncology|April 25, 2009
Meta-analysis for the evaluation of surrogate endpoints in cancer clinical trialsQian Shi, Daniel J Sargent
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 2008
New lessons from "old" chemotherapy in colorectal cancerAxel Grothey, Daniel J Sargent
Future Medicinal Chemistry|June 2, 2012
From isolated hypotheses to connected practical studies: statisticians' role in a seamless targeted therapy developmentQian Shi, Daniel J Sargent
The New England Journal of Medicine|July 23, 2004
New treatment options for colorectal cancerCharles Erlichman, Daniel J Sargent
Clinical Advances in Hematology & Oncology : H&O|September 10, 2015
Key statistical concepts in cancer researchQian Shi, Daniel J Sargent
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 24, 2005
FOLFOX for stage II colon cancer? A commentary on the recent FDA approval of oxaliplatin for adjuvant therapy of stage III colon cancerAxel Grothey, Daniel J Sargent
Chinese Clinical Oncology|April 6, 2015
Overview: biostatistician's role in oncology clinical trials-strive for sound, efficient and practical studiesQian Shi, Daniel J Sargent
Pageof 30

Showing results (1-10 of 295) with videos related to

Sort By:
Pageof 30
Clinical Advances in Hematology & Oncology : H&O|September 17, 2005
Novel endpoints in phase III clinical trialsDaniel J Sargent
Clinical Advances in Hematology & Oncology : H&O|October 2, 2008
Advances in defective mismatch repair colon cancerDaniel J Sargent
Nature Reviews. Clinical Oncology|December 1, 2010
Chemotherapy: Failure of bevacizumab in early-stage colon cancerDaniel J Sargent
International Journal of Clinical Oncology|April 25, 2009
Meta-analysis for the evaluation of surrogate endpoints in cancer clinical trialsQian Shi, Daniel J Sargent
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 2008
New lessons from "old" chemotherapy in colorectal cancerAxel Grothey, Daniel J Sargent
Future Medicinal Chemistry|June 2, 2012
From isolated hypotheses to connected practical studies: statisticians' role in a seamless targeted therapy developmentQian Shi, Daniel J Sargent
The New England Journal of Medicine|July 23, 2004
New treatment options for colorectal cancerCharles Erlichman, Daniel J Sargent
Clinical Advances in Hematology & Oncology : H&O|September 10, 2015
Key statistical concepts in cancer researchQian Shi, Daniel J Sargent
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 24, 2005
FOLFOX for stage II colon cancer? A commentary on the recent FDA approval of oxaliplatin for adjuvant therapy of stage III colon cancerAxel Grothey, Daniel J Sargent
Chinese Clinical Oncology|April 6, 2015
Overview: biostatistician's role in oncology clinical trials-strive for sound, efficient and practical studiesQian Shi, Daniel J Sargent
Pageof 30